Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

APOLLON GENEVAX VACCINE TO ENTER CLINIC IN MAY FOR HIV AND T CELL LYMPHOMA; "GENERIC" MANUFACTURING PROVIDES INEXPENSIVE SUPPLY OF GENE THERAPY PRODUCT

Executive Summary

Clinical trials of facilitated DNA Genevax products for HIV infection and T cell lymphoma could begin by the end of May, according to the corporate sponsor, Apollon, Inc. The Malvern, Penn.-based firm filed INDs in late 1994 for Genevax products for the two indications. Genevax vaccine products use specific sequences of DNA to elicit responses from the immune system when injected intramuscularly.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel